title: The effect of estrogen in a man with Parkinson's disease and a review of its therapeutic potential.
abstract: Estrogen has been implicated in controlling the pathogenesis and symptoms of Parkinson's disease (PD) in women. Here, we report a 53-year-old male with PD who underwent estrogen therapy with estradiol (E2). Within a month, he exhibited increased dyskinesias. His medication was reduced by 35% from a levodopa equivalent dose (LED) of 820-535 over three months, which overall improved his motor fluctuations and dyskinesias. Therefore, E2 therapy could have therapeutic potential in males with PD.
authors.affiliation: Movement Disorders Center, Colorado Neurological Institute , Englewood, CO , USA.
authors.forename: Chris
authors.initials: C
authors.lastname: Adams
authors.forename: Rajeev
authors.initials: R
authors.lastname: Kumar
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use; D004343:Drug Implants; D004967:Estrogens / Q000627:therapeutic use*; D005262:Feminization / Q000139:chemically induced; D005783:Gender Identity; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D013148:Spironolactone / Q000627:therapeutic use
chemical_list: D000978:Antiparkinson Agents; D004343:Drug Implants; D004967:Estrogens; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D007980:Levodopa